REGN9933
- Generic Name
- REGN9933
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT06444178
- Locations
- 🇬🇧
Fortrea Clinical Development, Leeds, United Kingdom
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Phase 2
Recruiting
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 195
- Registration Number
- NCT06299111
- Locations
- 🇮🇱
Lanadio Medical Center, Netanya, Israel
🇨🇦London Health Sciences Centre, London, Ontario, Canada
🇧🇬Sveta Sofia Hospital, Sofia, Bulgaria
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 373
- Registration Number
- NCT05618808
- Locations
- 🇧🇬
MBAL Heart and Brain Hospital, Pleven, Bulgaria
🇧🇪Ziekenhuis Oost-Limburg- Campus Sint-Jan, Genk, Limburg, Belgium
ðŸ‡ðŸ‡ºDepartment of Orthopedics, Somogy County Mór Kaposi Teaching Hospital, Kaposvar, Hungary
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT05102136
- Locations
- 🇧🇪
Regeneron Study Site, Edegem, Antwerp, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath